Clinical trials
Aggression clinical trials
Below are recruiting aggression clinical trials, each written for real people, not researchers. We’re tracking 88 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07434479Recruiting
Virtual reality mindfulness for aggression in schizophrenia
This study tests whether a virtual reality mindfulness program can help people with schizophrenia who have problems with impulsive aggression. You would use a VR headset for relaxation exercises and answer questions about your mood and behavior.
New York, New YorkAges 18–64 - NCT07487272Recruiting
Cell mapping in gum disease tissues
This study looks at the cells in gum tissue from people with different types of periodontitis (aggressive or chronic) and healthy gums. By understanding which cells are active and how they interact, researchers hope to find better ways to diagnose or treat gum disease.
Hangzhou, ZhejiangAges 20–40 - NCT04732052Recruiting
tDCS treatment for adults with developmental disabilities and aggression
This trial tests whether a non-painful brain stimulation treatment (tDCS) can reduce aggressive behaviors in adults with developmental disabilities. It’s meant for people who have had aggression in the last month and can safely receive the stimulation.
Kingston, OntarioAges 18–65 - NCT07755176Enrolling by invitation
Desmoid tumor ablation recovery survey
This study follows patients with desmoid tumors who are having a procedure called ablation, which uses heat or cold to destroy the tumor. The study asks patients about their symptoms and quality of life after the procedure to see how well it works.
Rochester, MinnesotaAges 18 years+ - NCT07704918Recruiting
Study: Lowering cholesterol during melanoma immunotherapy
This study tests whether giving aggressive cholesterol-lowering medication to people starting immunotherapy for melanoma can improve heart health. It may help reduce the risk of heart problems during cancer treatment.
Aurora, ColoradoAges 55 years+ - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Tucson, ArizonaAges 18 years+ - NCT06607731Recruiting
Alcohol gel treatment for aggressive angiomas
This trial studies a treatment using a special gelled alcohol to shrink aggressive angiomas (abnormal blood vessel growths). It aims to see if the procedure is safe, feasible, and works well.
Saint-Priest-en-JarezAges 18 years+ - NCT05925101Recruiting
Studying ways to reduce frequent behavior spikes in children
This study looks at basic and applied methods to understand “extinction bursts,” times when a hard-to-control behavior may briefly get worse before it improves. It may help families and clinicians choose safer, more effective behavior supports for children with very frequent problem behaviors.
Somerset, New JerseyAges 3–17 - NCT05887973Recruiting
Youth gun violence prevention program in Washington, DC
This trial is focused on preventing firearm violence by addressing underlying causes among youth taking part in a specific DC grassroots program. If you’re a youth involved with that program in Washington, DC, this study may fit you.
Ann Arbor, MichiganAges 14–24 - NCT06271057RecruitingPhase 2
Golcadomide after CAR T-cell for high-risk large B-cell lymphoma
This trial tests a new drug, golcadomide, given after CAR T-cell therapy to prevent relapse in people with aggressive large B-cell lymphoma who are at high risk. If you've had or are about to receive CAR T-cells, this study may help keep your lymphoma in remission.
CréteilAges 18 years+ - NCT05928247Recruiting
Behavior program for frequent challenging behaviors in children
This trial tests a structured (manualized) assessment and treatment approach for children who have very frequent challenging behaviors despite prior help. It aims to reduce these behaviors and improve daily functioning by targeting what keeps the behavior going.
Somerset, New JerseyAges 3–17 - NCT05563558RecruitingPhase 2
Testing pembrolizumab plus chemotherapy for aggressive metastatic prostate cancer
This Phase 2 trial tests pembrolizumab together with carboplatin and cabazitaxel in men with aggressive, metastatic prostate cancer that has become resistant to hormone therapy. It may help shrink tumors and improve outcomes for people with hard-to-treat forms of prostate cancer.
MadridAges 18 years+ - NCT05537610Recruiting
Test a behavior strategy for frequent self-injury
This study looks at how to reduce serious problem behaviors (including self-injury) in children who have it many times per day even after previous treatment. It may help if your child’s behavior is driven by social attention or other positive effects and they can stay on the same supports, school plan, and medicines during the study.
Somerset, New JerseyAges 3–17 - NCT05145868Recruiting
Text-message program to reduce alcohol-fueled partner violence
This trial tests whether a “just-in-time” text-message support program can help reduce alcohol-facilitated intimate partner violence you may have caused. It’s focused on people who drink heavily at times, have recent relationship violence history, and can receive texts for about 30 days.
Atlanta, GeorgiaAges 18–30 - NCT04052048Recruiting
Active surveillance prostate cancer test registry study
This study enrolls men with low-risk prostate cancer who are either staying on active surveillance or planning surgery soon. It uses a new “SNEP assay” test to help monitor prostate cancer over time and may improve how doctors track risk.
Royal Oak, MichiganAges 40–80 - NCT04045600Recruiting
Refining communication training for kids with behavior challenges
This study tests an improved version of functional communication training for children ages 3 to 17 whose destructive behavior (like hitting or yelling) happens often and is fueled by social attention. It aims to help children learn better ways to get attention instead of using hard-to-manage behaviors.
Somerset, New JerseyAges 3–17 - NCT06158880Recruiting
Alcohol and men's sexual risk behaviors
This study looks at how alcohol affects men's decisions about sex, especially risky behaviors like not using condoms. If you join, you may help researchers understand how to reduce HIV and STI risk.
Phoenix, ArizonaAges 21–30 - NCT07168980RecruitingPhase 2/Phase 3
Chemotherapy plus rituximab for aggressive B-cell lymphoma in kids
This trial tests whether adding rituximab to standard chemotherapy works better for children and teens with aggressive B-cell non-Hodgkin lymphoma. It may be a good option if your child's cancer cells have the CD20 protein and they haven't been treated with rituximab before.
Shanghai, Shanghai MunicipalityAges Up to 18 years - NCT05685173RecruitingPhase 1
Study safety of REGN5837 with odronextamab in adult B-cell lymphoma
This Phase 1 trial tests whether a new medicine (REGN5837) given with odronextamab is safe in adults with aggressive B-cell non-Hodgkin lymphoma. It may help researchers learn if this combination can work for patients whose disease has progressed after earlier treatments.
Duarte, CaliforniaAges 18 years+ - NCT05783804Recruiting
Early cholesterol-lowering to help reverse artery plaque
This trial studies whether starting strong cholesterol-lowering treatment early can reduce or reverse plaque in the arteries. It may help protect the heart over time, especially for people with inherited high cholesterol.
Amsterdam, North HollandAges 18–50 - NCT07059741Recruiting
Radiation, stem cell transplant, and CAR-T for aggressive B-cell lymphoma
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
Suzhou, JiangsuAges 18 years+ - NCT07197307RecruitingPhase 2
Study of two targeted drugs for relapsed aggressive B-cell lymphoma
This study tests a new combination of two drugs—loncastuximab tesirine (an antibody-drug conjugate) and epcoritamab (a bispecific antibody)—for people whose aggressive B-cell lymphoma has returned or not responded to prior treatment. The goal is to see if the combination is safe and effective.
AachenAges 18 years+ - NCT07176689RecruitingPhase 4
Nirogacestat for desmoid tumors in premenopausal women
This trial tests a drug called nirogacestat to see if it can help premenopausal women with desmoid tumors (a type of non-cancerous growth) that are causing symptoms or getting worse. It aims to offer a new treatment option for those who need systemic therapy.
BrusselsAges 18–40 - NCT06422806RecruitingPhase 3
Immunotherapy plus chemo for aggressive sarcoma
This trial compares a combination of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) versus chemotherapy alone for people with aggressive, poorly differentiated sarcomas that have spread or cannot be removed. The goal is to see if adding immunotherapy helps shrink tumors or slow their growth better than chemotherapy alone.
Phoenix, ArizonaAges 18 years+
Hear when a new Aggression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for aggression?
- Yes. Clin2 currently lists 88 recruiting aggression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a aggression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a aggression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.